Metabolic Heterogeneity in Diffuse Large B-Cell Lymphoma Cells Reveals an Innovative Antimetabolic Combination Strategy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Feb 13

PMID 39941763

Authors

Leonardo Lordello

Stephanie Nuan-Aliman

Karoline Kielbassa-Elkadi

Aurelie Montagne

Konstantina Kotta

Isabelle Martins

Eva Pinto Jurado

Cedric Caradeuc

Jacqueline Lehmann-Che

Jose Angel Martinez-Climent

Veronique Meignin

Nicolas Giraud

Guido Kroemer

Gildas Bertho

Catherine Thieblemont

Veronique Baud

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, characterized by aggressive and heterogeneous tumors originating from B-cells. Especially in patients with relapsed or refractory (R/R) disease, DLBCL remains a challenging cancer to treat. Metabolic reprogramming is a hallmark of malignant cells. Our research focuses on developing strategies to enhance clinical outcomes for R/R DLBCL patients by targeting metabolic vulnerabilities. We investigated the effects of combining metformin and L-asparaginase, two FDA-approved antimetabolic drugs, on DLBCL cell metabolism and survival. Nuclear magnetic resonance (NMR) spectroscopy was employed to assess metabolic disturbances induced by the drug combination. The impact on lipid metabolism, glycolysis, glutaminolysis, the tricarboxylic acid (TCA) cycle, and antioxidant responses was examined. Induction of apoptosis was evaluated by FACS analysis. The combination of metformin and L-asparaginase strongly sensitized DLBCL cells to apoptosis, independently of their oxidative phosphorylation (OxPhos) or BCR/glycolytic status. NMR spectroscopy revealed that this combination induces broader metabolic disturbances than either drug alone. It disrupts lipid metabolism by altering levels of phospholipids, cholesterol, and fatty acids. Additionally, it counteracts the pro-glycolytic effect of metformin, decreases glycolysis, and reduces glutaminolysis. It also affects the TCA cycle and antioxidant responses, critical for cellular energy production and redox balance. Furthermore, this combination interferes with two key cancer survival pathways, mTORC1 and MAPK signaling. Importantly, proof of principle for its beneficial effect was demonstrated in DLBCL patients. Combining metformin and L-asparaginase affects DLBCL cell survival by targeting multiple metabolic pathways and may represent a novel therapeutic approach for R/R DLBCL patients.

References

Cunha Junior A, Pericole F, Carvalheira J . Metformin and blood cancers. Clinics (Sao Paulo). 2018; 73(suppl 1):e412s. PMC: 6113924. DOI: 10.6061/clinics/2018/e412s. View

Gifford G, Gifford A, Chen Q, Shen Y, Gabrielli S, Gill A . Fatty acid synthase and adenosine monophosphate-activated protein kinase regulate cell survival and drug sensitivity in diffuse large B-cell lymphoma. Leuk Lymphoma. 2020; 61(8):1810-1822. DOI: 10.1080/10428194.2020.1742899. View

Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A . Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011; 43(9):830-7. PMC: 3297422. DOI: 10.1038/ng.892. View

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

Swerdlow S, Campo E, Pileri S, Lee Harris N, Stein H, Siebert R . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20):2375-90. PMC: 4874220. DOI: 10.1182/blood-2016-01-643569. View

McDonald G, Chubukov V, Coco J, Truskowski K, Narayanaswamy R, Choe S . Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase. Mol Cancer Ther. 2020; 19(12):2502-2515. DOI: 10.1158/1535-7163.MCT-20-0550. View

Liu X, Wang L, Jiang W, Lu W, Yang J, Yang W . B cell lymphoma with different metabolic characteristics show distinct sensitivities to metabolic inhibitors. J Cancer. 2018; 9(9):1582-1591. PMC: 5950587. DOI: 10.7150/jca.24331. View

Wang Y, Maurer M, Larson M, Allmer C, Feldman A, Bennani N . Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. Br J Haematol. 2019; 186(6):820-828. PMC: 6731132. DOI: 10.1111/bjh.15997. View

Sehn L, Salles G . Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384(9):842-858. PMC: 8377611. DOI: 10.1056/NEJMra2027612. View

10.

Roux P, Blenis J . ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004; 68(2):320-44. PMC: 419926. DOI: 10.1128/MMBR.68.2.320-344.2004. View

11.

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

12.

Takahashi H, Inoue J, Sakaguchi K, Takagi M, Mizutani S, Inazawa J . Autophagy is required for cell survival under L-asparaginase-induced metabolic stress in acute lymphoblastic leukemia cells. Oncogene. 2017; 36(30):4267-4276. PMC: 5537607. DOI: 10.1038/onc.2017.59. View

13.

Jacob D, Deborde C, Lefebvre M, Maucourt M, Moing A . NMRProcFlow: a graphical and interactive tool dedicated to 1D spectra processing for NMR-based metabolomics. Metabolomics. 2017; 13(4):36. PMC: 5313591. DOI: 10.1007/s11306-017-1178-y. View

14.

Derudder E, Dejardin E, Pritchard L, Green D, Korner M, Baud V . RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem. 2003; 278(26):23278-84. DOI: 10.1074/jbc.M300106200. View

15.

Nuan-Aliman S, Bordereaux D, Thieblemont C, Baud V . The Alternative RelB NF-kB Subunit Exerts a Critical Survival Function upon Metabolic Stress in Diffuse Large B-Cell Lymphoma-Derived Cells. Biomedicines. 2022; 10(2). PMC: 8961793. DOI: 10.3390/biomedicines10020348. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

18.

Parmentier J, Maggi M, Tarasco E, Scotti C, Avramis V, Mittelman S . Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines. Leuk Res. 2015; 39(7):757-62. PMC: 4458142. DOI: 10.1016/j.leukres.2015.04.008. View

19.

Cluntun A, Lukey M, Cerione R, Locasale J . Glutamine Metabolism in Cancer: Understanding the Heterogeneity. Trends Cancer. 2017; 3(3):169-180. PMC: 5383348. DOI: 10.1016/j.trecan.2017.01.005. View

20.

Pavlova N, Zhu J, Thompson C . The hallmarks of cancer metabolism: Still emerging. Cell Metab. 2022; 34(3):355-377. PMC: 8891094. DOI: 10.1016/j.cmet.2022.01.007. View